Immunotherapy with monoclonal antibodies targeting cytotoxic T-lymphocyte antigen 4 (CTLA-4) or prgrammed cell death 1 (PD-1) has improved the survival of patients with metastatic melanoma. These agents carry a certain risk of adverse immune-related events.
Introduction
Immunotherapy with monoclonal antibodies such as ipilimumab (which targets CTLA-4), or pembrolizumab and nivolumab (which target PD-1) has revolutionized the management of melanoma. Data accumulating from clinical trials suggests the efficacy of these so-called "checkpoint inhibitors" in treating metastatic melanoma but less is known about the risk of immune-related adverse events (IrAEs). As some of the more common IrAEs, these agents may cause skin rash or colitis, while hypophysitis, hepatitis, nephritis, and neuropathy are less common. Very little is known about CNS-related IrAEs. A recent double-blind phase 3 trial comparing combined nivolumab and ipilimumab vs. monotherapy in untreated melanoma showed that immunologic grade 3 or 4 adverse events are more frequent in the combined group (nivolumab + ipilimubab: 55.0% ; nivolumab: 16.3% ; ipilimumab: 27.3%) (1) . We report the case of a 60 year-old man who succumbed to progressive and subacute CNS demyelination that developed while he was receiving nivolumab following ipilimumab for metastatic melanoma. CNS demyelination has never been reported as a side effect of anti-PD-1 therapy although a case of encephalopathy with a reversible splenial lesion was described in association with ipilimumab (2) . As the use of these agents increases, it is important to be aware of this rare but severe potential complication.
Case Presentation
A 60 year-old white man was diagnosed with a low-risk in situ cutaneous melanoma presence of widespread demyelination in the right frontal and left temporo-parietal white matter with infiltration of macrophages containing myelin debris, reactive astrocytes, focal perivascular lymphoid inflammation, and areas of early cavitation (Fig. 2, A-F 
Discussion
Although immunotherapy has revolutionized the treatment of cancers such as melanoma, it can also cause serious IrAEs. We present the case of a 60 year-old man with metastatic melanoma who, after three months of nivolumab therapy post-ipilimumab, The CNS is under continual immune surveillance to detect and eliminate potential mediators of infection and damage (10) . PD-1 and PD-L1 have been studied extensively in animal models of autoimmunity and in multiple sclerosis (MS). In experimental autoimmune encephalomyelitis (EAE), the interaction between PD-1 and PD-L1 influences disease severity. In particular, PD-1 blockade results in a more severe form of EAE (11) . On the other hand, high PD-L1 expression prompts a primary tolerogenic program in EAE (12) .
In MS, increased expression of PD-1 and PD-L1 results in decreased T cell proliferation and increased apoptosis of MBP-specific cells, which is associated with disease remission (13) .
In vitro experiments showed that blocking PD-L1 on human endothelial cells results in increased transmigration of activated T cells (14) (15) . In our case, the radiographic appearance of the demyelinating lesions did not have the typical characteristics of MS; the diffusion restriction and enhancement patterns were consistent with subacute tumefactive demyelination.
Neurological complications of checkpoint inhibitors are rare, and have mostly been reported to involve the peripheral nervous system. For example, IrAEs for ipilimumab include Guillain-Barré syndrome (16) (17) (18) , multifocal radiculoneuropathy and chronic inflammatory demyelinating polyneuropathy (CIDP) (19). In the case with nerve pathology available (17) , the biopsy showed inflammation around endoneurial microvessels and subperineurial edema and inflammation. A patient on ipilimumab developed mild encephalopathy with a lesion in the splenium of the corpus callosum (2) that resolved after methylprednisolone. What sets our case apart from these reported cases is the progressive nature of the patient's left frontal lesion that showed resistance to immunosuppressive therapy and ultimately led to the fatal outcome. Whether this is an effect of nivolumab alone or also the result of the preceding ipilimumab remains unclear. The interval between the two drugs was short (2 months), therefore residual ipilimumab effects cannot be excluded.
The patient's large right frontal lesion continued to progress when on immunosuppressive treatment, whereas the left temporo-parietal lesion improved radiologically. Histologically, 
the right frontal lesion showed extensive necrosis and astrogliosis, whereas the left temporo-parietal lesion contained sheets of macrophages, an absence of necrosis, and no significant astrogliosis. These histological differences may explain the imaging differences.
Only safety data from larger studies and potentially postmarketing experience will define the exact risk of nivolumab-related immunopathologies. Nevertheless, our case provides plausible evidence for aberrant immune system activation and CNS demyelination after treatment with this antibody to PD-1. We suggest that pretreatment with ipilimumab may have also played a role in the development of demyelination. The novelty of these treatment combinations requires further study to know if the sequence of ipilimumab followed by nivolumab versus nivolumab followed by ipilimumab is associated with more severe side effects. We do not know whether our patient's ethnic background and positive family history of MS were contributing risk factors.
The published algorithms to manage autoimmune complications from ipilimumab and nivolumab, as well as guidelines to treat MS were used to plan therapy for our patient.
High dose steroids and IVIG may have transiently improved the clinical situation in our patient, but did not prevent his death. Additional medications, such as cyclophosphamide, mycophenolate mofetil and tacrolimus might find use as part of a regimen to control T-cell proliferation, although experience with these drugs for this indication is currently limited.
After consultation with the patient's family, we agreed to discontinue treatment after the second attempt with IVIG, but the role of plasmapheresis and other immunotherapies needs to be evaluated in similar cases. With additional cases of demyelination anticipated as the use of these agents increases, an effective treatment algorithm will likely evolve. 
